TScan Therapeutics, Inc.
TScan Therapeutics, Inc. (TCRX): 32 pipeline candidates · ~16 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
16.4 months
D/E 1.08
Lead: Phase 1
32 candidates
N/A
2 buys · 0 sells (180d)
A transparent, data-derived signal for TScan Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$62.1M
Cash
$133.1M
Quarterly Burn
$24.3M
Runway
16.4 mo
Revenue
$982K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (32 candidates)
| Drug | Phase |
|---|---|
| tsc-100 | Phase 1 |
| tsc-101 | Phase 1 |
| tsc-102-a01 | Phase 1 |
| tsc-102-a03 | Phase 1 |
| tsc-102-a0301 | Phase 1 |
| tsc-200-a0201 | Phase 1 |
| tsc-200-a0201 + tsc-201-b0702 | Phase 1 |
| tsc-200-a0201 + tsc-202-a0201 | Phase 1 |
| tsc-200-a0201 + tsc-203-a0201 | Phase 1 |
| tsc-200-a0201 + tsc-204-a0101 | Phase 1 |
Showing 10 of 32 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
58
Total value held
$32.2M
| Holder | Shares | Value |
|---|---|---|
| lynx1 capital management lp | 8,019,148 | $8.1M |
| bvf inc/il | 5,564,290 | $5.6M |
| vanguard capital management llc | 4,308,512 | $4.4M |
| baker bros. advisors lp | 2,784,792 | $2.8M |
| blackrock, inc. | 1,840,952 | $1.9M |
| millennium management llc | 1,460,285 | $1.5M |
| renaissance technologies llc | 1,364,783 | $1.4M |
| two sigma investments, lp | 1,209,009 | $1.2M |
| jacobs levy equity management, inc | 808,356 | $816K |
| dc funds, lp | 630,000 | $630K |
Showing top 10 of 58 institutional holders of TScan Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in TScan Therapeutics, Inc.'s pipeline?
TScan Therapeutics, Inc. (TCRX) has 32 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is TScan Therapeutics, Inc.'s lead drug candidate?
TScan Therapeutics, Inc.'s most advanced tracked candidate is tsc-100 (Phase 1) for AML.
What is TScan Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, TScan Therapeutics, Inc. has approximately 16.4 months of cash runway.
What is TScan Therapeutics, Inc.'s market capitalization?
TScan Therapeutics, Inc.'s market capitalization is approximately $62.1M.
Who is the CEO of TScan Therapeutics, Inc.?
Dr. Gavin MacBeath Ph.D. is the chief executive officer of TScan Therapeutics, Inc. (TCRX).
Get the full picture on TScan Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.